Home > Dermatology > Vendors > Micreos

Micreos: Steroid-Free Skincare with Gladskin

Follow Micreos on :

Mr. Mark Offerhaus, CEO, MicreosMr. Mark Offerhaus, CEO
A kid suffering from eczema spends sleepless nights due to itching and inflammation. With the symptoms worsening, her parents become unnerved. How to reduce the inflammation? How to relieve the kid from eczema?

While corticosteroids have prevailed as the conventional answer to these predicaments, steroid hormones, however, only act by suppressing the immune system and leave what we now know is the actual trigger of the flares, a bacterial species called Staphylococcus (S.) aureus, unscathed. While repeated use of corticosteroids fails to address the root cause of the skin disease, patients are forced to be content with relief that lasts only for few moments and leads to side effects in the long run.

Gladskin, the steroid-free skincare product specifically targeting S. aureus, emerges as the remedy that can cure a gamut of skin diseases aggravated by these bacteria, including eczema. Developed by Netherlands-based Micreos, Gladskin also is the wholesome alternative to the existing skincare products which are laden with antibiotics to treat infected acne and rosacea. Gladskin is care and cure for these types of skin diseases, as it contains Staphefekt SA.100, an enzyme that eliminates S. aureus bacteria that cause inflammation, swelling, itchiness, pain, and other major symptoms of inflammatory skin diseases. “Gladskin is the only healthy option in today’s market which is replete with corticosteroids and ineffective antibiotics for skincare and treatment,” says doctor Bjorn Herpers, Clinical Microbiologist and Chief Medical Advisor of Micreos.

The striking feature of Gladskin is that it neither affects the patient’s immune system nor kills beneficial bacteria, which sets it apart from corticosteroids and antibiotics. Gladskin’s major constituent Staphefekt SA.100 is a so called endolysin, an active enzyme.

Gladskin is the only healthy option in today’s market which is replete with corticosteroids and ineffective antibiotics for skincare and treatment


The enzyme sets in action and attacks S. aureus within few milliseconds of applying Gladskin to the affected area. Staphefekt SA.100’s action on S. aureus is similar to punching a hole in a balloon. It targets the cell structure of S. aureus, degrades it, and quickens the process of eliminating the bacteria from the skin to reduce the inflammatory symptoms they are causing.

Micreos has ensured the success of Gladskin by testing the effectiveness of Staphefektin different environments. For instance, the researchers affirmed Staphefekt’s efficacy to eliminate S. aureus, while leaving beneficial bacteria unharmed. Additionally, the enzyme proved to provide an edge over the antibiotics as it was even capable of killing the antibiotic resistant variant of S. aureus, the superbug MRSA. Eventually, the firm tested the induction of resistance of S. aureus to the enzyme in a laboratory. Although the bacteria were given many repeated exposures against Staphefekt, they could not mount resistance to the enzyme. The outcome was contrary to what was seen with antibiotics, where repeated exposure lead to higher resistance from the bacteria. Staphefekt’s unique characteristics make Gladskin an ideal candidate for long term maintenance treatment of inflammatory skin conditions, as it spares the beneficial microbiome and does not induce resistance.

The cutting-edge product has already won appreciation from business and medical communities and has been regarded as Europe’s most impactful innovation. The firm’s skincare product was featured on BBC Two’s Trust me I’m a Doctor for its novelty. The show paved a path for Gladskin’s quick acceptance across the U.K.

Micreos aims to introduce the product for treating other medical conditions like diabetic wound infections and vascular ulcers in which S. aureus is expected to proliferate. The company also plans to make available its proprietary product to patient communities across the globe.
Share this Article:
Top 10 Dermatology Solution Companies - 2019

Company
Micreos

Headquarters
Den Haag, Zuid Holland

Management
Mr. Mark Offerhaus, CEO

Description
Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. With Micreos endolysin technology, for the first time only the unwanted bacteria can be killed - including antibiotic resistant strains - while preserving the beneficial bacteria, essential for our health. Micreos' Staphefekt SA.100 is an enzyme (endolysin), that targets only Staphylococcus aureus. Marketed under the Gladskin brand, it is the world's first endolysin registered for human use and has had a life-changing impact for thousands of people suffering from inflammatory skin conditions such as eczema, inflammatory acne and rosacea and resistant wound infections